Skip to main content
. 2022 May 4;9:835257. doi: 10.3389/fmed.2022.835257

Figure 3.

Figure 3

(A) Comparison between IgE levels during application of omalizumab and MP. (B) FEV1 and FEV1/FVC test results in different periods. (C) ACT score results in different periods.